July 27-29, 2021 | Virtual Event
www.informaconnect.com/formulary-access/
Formulary, Reimbursement and Access Summit provides a forum for industry to convene, benchmark and gain strategies to explore new and impending access and managed market challenges within the value-based landscape while providing insights on valuable patient services and support programs, healthcare market coverage and strategies to improve overall access and reimbursements of commercialized drugs.
Drug Channels readers are eligible for an exclusive savings of 10% off* the current rate by using promo code 21FRADC10, be sure to reserve your seat today!
Gain critical insights from a distinguished speaking faculty including:
- Michael Thompson, President & CEO, National Alliance of Healthcare Purchaser Coalitions
- D.R. McCale III, MDY, RMC, Director, Market Access and Reimbursement, Akcea Therapeutics
- Shannon D. Ashmon, MBA, Senior Manager, Access & Reimbursement, Oncology Business Unit, Eisai, Inc.
- Peter Avalos, National Reimbursement Director, Daiichi Sankyo, Inc.
- Jeff Blake, Senior Vice President, Payer Relations, Hemophilia Alliance
- Shawn Gremminger, Health Policy Director, Pacific Business Group on Health
- And many more!
- Formulary Insights – Advancements in Design and Management
- The Future of Rebate Reform – Explore Current and Pending Legislation
- Assess the Landscape for Prior Authorization and Reimbursement Support - Reexamining the Roles of the Manufacturer and the Pharmacy
- Value-Based Contracting Frameworks and Considerations
- Digital Therapies and Telehealth – Define their Role in the Evolving Healthcare Landscape
- And so much more!
Drug Channels readers are eligible for an exclusive savings of 10% off* the current rate by using promo code 21FRADC10, be sure to reserve your seat today!
*Offer may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid academic/non-profit registrations.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.
No comments:
Post a Comment